Axa S.A. Enanta Pharmaceuticals Inc Transaction History

Axa S.A.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$20.68 - $39.85 $647,284 - $1.25 Million	31,300 New	31,300 $669,000
Q3 2022 Nov 14, 2022	BUY	$48.29 - $71.27 $299,398 - $441,874	6,200 New	6,200 $322,000
Q3 2021 Nov 15, 2021	SELL	$41.02 - $58.65 $2.56 Million - $3.66 Million	-62,400 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$43.76 - $53.11 $1.02 Million - $1.23 Million	23,253 Added 59.4%	62,400 $2.75 Million
Q1 2021 May 14, 2021	BUY	$41.69 - $54.95 $1.29 Million - $1.71 Million	31,047 Added 383.3%	39,147 $1.93 Million
Q4 2020 Feb 12, 2021	BUY	$41.16 - $47.47 $12,347 - $14,241	300 Added 3.85%	8,100 $341,000
Q2 2020 Aug 14, 2020	BUY	$46.37 - $57.58 $361,686 - $449,124	7,800 New	7,800 $392,000
Q1 2019 May 14, 2019	SELL	$69.08 - $105.66 $227,964 - $348,678	-3,300 Closed	0 $0
Q4 2018 Feb 13, 2019	SELL	$65.41 - $84.65 $784,920 - $1.02 Million	-12,000 Reduced 78.43%	3,300 $234,000
Q3 2018 Nov 08, 2018	SELL	$85.46 - $126.37 $179,466 - $265,377	-2,100 Reduced 12.07%	15,300 $1.31 Million
Q2 2018 Aug 13, 2018	BUY	$81.85 - $120.51 $1.42 Million - $2.1 Million	17,400 New	17,400 $2.02 Million

110

21.1M

4.8K

4.6K

Ticker ENTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,724,900
Market Cap $194M
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.